LOUISVILLE, Ky. — Sex, race and ethnicity were associated with varying biomarker test results among adults with severe asthma, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

“Biomarker testing is a routine part of specialist management for severe asthma, as it can be used to predict response to treatment and the course of disease,” Donna Carstens, MD, senior medical director of respiratory, Fasenra at AstraZeneca, said during her presentation.

“However, currently, there are few data that describe real-world biomarker test results for patients with severe asthma in routine practice within the specialist setting and how they may vary by demographic characteristics,” Carstens continued.

The researchers examined findings from 3,222 adults (mean age, 54.3 years; 73.6% white; 57.2% commercially insured) diagnosed with severe asthma but not receiving biologics or systemic corticosteroids enrolled in the ongoing CHRONICLE observational study between February 2018 and February 2022.

During the 12 months before enrollment, 3,204 patients had biomarker testing, including 57% with one or more blood eosinophil count (BEC) tests, 28% with one or more fractional exhaled nitric oxide (FeNO) tests, and 42% with one or more total IgE tests performed.

At any point during the study, 2,180 patients had biomarker testing, including 68% with one or more BEC tests, 32% with one or more FeNO tests, and 46% with one or more total IgE level tests.

BEC results showed 36% of patients had 300 cells/µL or more, 24% with 150 cells/µL to 299 cells/µL and 40% with less than 150 cells/µL.

FeNO results showed 58% of patients at 50 ppb or higher, 25% at 25 to 49 ppb and 17% at less than 25 ppb.

Total IgE results showed 23% of patients at 400 IU/mL or higher, 23% at 150 to 399 IU/mL, 33% at 30 to 149 IU/mL, and 21% at less than 30 IU/mL.

Men had higher median BEC (299 cells/µL vs. 221 cells/µL), FeNO (26 ppb vs. 19 ppb) and total IgE (230 IU/mL vs. 110 IU/mL) test results than women.

Also, Black patients had lower median BEC (180 cells/µL) than non-Hispanic white patients (241 cells/µL) and Hispanic patients (272 cells/µL). Hispanic patients had lower median FeNO (16 ppb vs. 20 ppb vs. 21 ppb) compared with Black and non-Hispanic white patients, whereas the latter had lower median total IgE (102 IU/mL vs. 185 IU/mL vs. 226 IU/mL) compared with Black and Hispanic patients.

“We believe these differences may be explained in part by the differential prevalence of allergic eosinophilic and T2-low phenotypes among subgroups,” Carstens said.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

” data-action=subscribe>
Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

American College of Allergy, Asthma & Immunology Annual Scientific Meeting